The quest for the next blockbuster drug is a high-stakes game in the pharma industry. Two main paths lead to this coveted prize: internal R&D, the detailed but potentially rewarding journey of developing drugs from scratch, and acquisitions, the quicker but pricier route of buying into existing biotechs with promising pipelines. Which is the smarter bet? The answer, like most things in life, is that it depends.